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Abstract
Glioblastoma, the most aggressive type of primary brain tumour, shows worse prognosis
linked to diabetes or obesity persistence. These pathologies are chronic inflammatory condi-
tions characterized by altered profiles of inflammatory mediators, including leptin and
secreted phospholipase A2-IIA (sPLA2-IIA). Both proteins, in turn, display diverse pro-can-
cer properties in different cell types, including astrocytes. Herein, to understand the underly-
ing relationship between obesity and brain tumors, we investigated the effect of leptin, alone
or in combination with sPLA2-IIA on astrocytoma cell functions. sPLA2-IIA induced up-regu-
lation of leptin receptors in 1321N1 human astrocytoma cells. Leptin, as well as sPLA2-IIA,
increased growth and migration in these cells, through activation/phosphorylation of key
proteins of survival cascades. Leptin, at concentrations with minimal or no activating effects
on astrocytoma cells, enhanced growth and migration promoted by low doses of sPLA2-IIA.
sPLA2-IIA alone induced a transient phosphorylation pattern in the Src/ERK/Akt/mTOR/
p70S6K/rS6 pathway through EGFR transactivation, and co-addition of leptin resulted in a
sustained phosphorylation of these signaling regulators. Mechanistically, EGFR transactiva-
tion and tyrosine- and serine/threonine-protein phosphatases revealed a key role in this lep-
tin-sPLA2-IIA cross-talk. This cooperative partnership between both proteins was also found
in primary astrocytes. These findings thus indicate that the adipokine leptin, by increasing
the susceptibility of cells to inflammatory mediators, could contribute to worsen the progno-
sis of tumoral and neurodegenerative processes, being a potential mediator of some obe-
sity-related medical complications.
Introduction
Over the last years, many studies have stated a harmful synergy among cancer, obesity and
diabetes: individuals with diabetes and elevated body mass index are more likely to develop
cancer; and cancer patients, who also suffer from diabetes or obesity, show a higher risk of
mortality than non-diabetic and non-obese ones [1–3]. According to this, a recent study has
demonstrated that in high grade glioma patients, pre-existing diabetes and obesity are inde-
pendent risk factors for early progression and death [4]. Glioblastoma is the most common
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primary adult brain cancer with an extremely poor prognosis. Although it rarely metastasizes,
it spreads aggressively within the brain, so it can rarely be totally removed using surgery. For
this reason, understanding the mechanisms underlying this prognosis is a major challenge in
order to find new strategies to control the neoplastic process.
Obesity is a systemic low-grade inflammatory disease characterised by sustained levels of
circulating inflammatory proteins [5]. This results in a pro-tumorigenic environment which
can play a role in malignant transformation and/or cancer progression. Among these active
biological molecules, leptin and secreted phospholipase A2-IIA (sPLA2-IIA, sPLA2) have been
found elevated in obese individuals and some forms of cancer [6–11].
Leptin plays an important role in the regulation of body weight homeostasis [12]. Classi-
cally produced by adipose tissue, leptin is released into the circulation to act both peripherally
and in the brain [13]. However, finding leptin in blood leaving the brain suggests that leptin
may also be synthesized by brain tissues [14]. In fact, in healthy individuals leptin released by
the brain makes up/constitutes more that 40% of the whole plasma leptin, being this contribu-
tion remarkably higher in obese than in non-obese males ref [15]. Beside its link to obesity,
leptin may also play a crucial role in cancer initiation, progression or in metastatic develop-
ment. The biological function of leptin is triggered through its cell surface receptors (ObR)
[16]. It has been described that the leptin/ObR system is over-expressed in brain cancer and its
expression correlates with the degree of malignancy [10]. Leptin can amplify some oncogenic
pathways via transactivation of receptors, and it may even cooperate with cytokines to amplify
the inflammatory response [17–19].
sPLA2-IIA is an acute phase reactant found increased in numerous inflammatory condi-
tions. Many studies suggest its involvement in carcinogenesis, although its specific role medi-
ating pro- or antitumoral signaling, depends on the type of cancer [8,9]. Its expression level
has been related to disease prognosis, and in some tumor types it is also considered a marker
of metastasis [20–22]. sPLA2-IIA leads to excessive proliferation and survival signals in
tumoral cells including astrocytomas [23].
Interestingly, individual effects of leptin and sPLA2-IIA have been studied in different
established cell lines in vitro. However, the precise interaction among them and how their sig-
naling cross-talk influences cell growth and migration is poorly understood, even though, in
pathological conditions, it is their interplay that may activate intracellular pathways converg-
ing to promote tumor progression and metastasis.
This study characterizes the link between leptin and sPLA2-IIA on 1321N1 astrocytoma
cells. Leptin not only increases cell growth, migration and activation of the classical prolifera-
tion cascades, but it also enhances biological responses of sPLA2-IIA by prolonging the tempo-
ral pattern of EGFR, ERK, Akt/mTOR and p70S6K/rS6 activation. This is the first evidence to
demonstrate the relationship between two proteins present in the tumor microenvironment,
leptin and sPLA2-IIA, and the effect of this tandem on tumor progression.
Materials and methods
Materials
A C127 mouse fibroblast cell line stably transfected with the coding sequence of sPLA2-IIA
from human placenta was kindly provided by Dr. Jean-Luc Olivier and used as a source of the
human recombinant enzyme, which was obtained and purified as described previously [24].
Rapamycin, leptin, ECL detection system, Hybond-P membrane and other chemicals were
from Sigma Chemical Co. PD98059 and AG1478 and AG1296 inhibitors were from Tocris
Bioscience. DMEM and the cell culture supplements, including foetal calf serum (FCS) were
from Lonza.
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Cell culture
1321N1 human astrocytoma cells, a gift from Dr. JH Brown (UCSD, San Diego, CA, USA),
were cultured in DMEM supplemented with 100 U/ml penicillin/streptomycin, and 10% heat-
inactivated fetal calf serum (FCS) at 37˚C in 5% CO2. Primary mouse astrocytes were obtained
as described previously [25]. More than 95% of cells were stained for astrocyte specific glial
fibrillary acidic protein (Santa Cruz Biotechnology Inc).
Primary astrocytes and astrocytoma cells were incubated in serum-free medium 24 h before
the experiments, and then stimulated as indicated, in the presence or absence of inhibitors.
Western blot analysis
Cells were lysed in Laemmli buffer and subjected to sPLA2-IIA SDS-polyacrylamide gel elec-
trophoresis. Western blot analysis was performed with the following antibodies: phospho-Akt
(Ser473), Akt, phospho-ERK1/2 (Thr202/Tyr204), phospho-P70S6K (Thr389), phospho-rS6
(Ser235/236) (Cell Signaling Technology, Inc), ERK (Zymed Laboratories), and actin (Santa
Cruz Biotechnology Inc). Protein levels were detected with HRP-conjugated secondary anti-
bodies, and visualized using the ECL detection system according to the manufacturer’s
instructions.
Flow cytometric analysis
Serum-starved cells were incubated in medium with EGF (0.4 μM), sPLA2-IIA (0,5 μg/ml),
PDGF (1 μM) or leptin (0.5 μM), for different periods of time at 37˚C. Cells to analyze the
expression of leptin receptor were fixed with 4% paraformaldehyde and 0.2% Triton X-100 in
PBS for 15 min at room temperature, before incubation with anti-mouse ObR antibody (R&D
Systems) for 1 h at 4˚C. For EGFR and Src phosphorylation analysis, cells were fixed in 4%
paraformaldehyde for 15 min, washed with PBS, permeabilized with 0.3% Triton X-100 for 5
min, washed, incubated with anti-phospho EGFR (Tyr1173), EGFR (Tyr845), EGFR (Tyr1068)
or Src (Tyr416) antibody (Santa Cruz Biotechnology Inc) for 1 h at 4˚C, and then with a fluores-
cein isothiocyanate (FITC)-labelled secondary antibody (Sigma) for 45 min at 4˚C. After wash-
ing, cells were analyzed with a Flow Cytometer (GalliosTM; Beckman Coulter). Data analysis
was performed using WinMDI 2.7 software.
Immunofluorescence studies
Serum-starved 1321N1 cells, on 18-mm cover glass coverslips, were fixed in cold 4% parafor-
maldehyde for 10 min, permeabilized in 0.3% Triton X-100 for 10 min and blocked with 3%
BSA for 1h. Immunostaining with ObR antibody (H-300; Santa Cruz Biotechnology Inc) was
performed at room temperature for 30 min, followed by incubation with FITC-conjugated sec-
ondary antibody. Cells were then analyzed under a Nikon Eclipse 90i (Nikon Instruments,
Inc.).
Proliferation assay
Cell proliferation was quantified using the Promega kit, Cell Titer 96RAqueous One Solution
Cell Proliferation Assay, according to the manufacturer’s recommendations. Briefly, serum-
starved 1321N1 astrocytoma cells, seeded in 96-well tissue culture plates (5×104 cells/ml), were
treated in triplicate with sPLA2-IIA, EGF, leptin or combinations, in the presence or absence
of inhibitors. After 24h of incubation, formazan product formation was assayed by recording
the absorbance at 490 nm in a 96-well plate reader, as an assessment of the number of metabol-
ically active cells.
Cross-Talk between leptin and sPLA2-IIA
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Chemotaxis assay
Cell migration assays were performed using 24-well Transwell plates with 8μm-pore polycar-
bonate membrane filters, following the manufacturer’s instructions. Lower wells were filled
with medium containing vehicle, 50% FCS or leptin, as indicated. Cells (1x106 cells/ml) were
added to the upper chamber. Before the migration assay was performed, and when indicated,
cells were pretreated for 30 min with selective inhibitors, and then stimulated with sPLA2-IIA
or leptin for 30 additional min. Migration was allowed for 4 h at 37˚C in 5% CO2. After incu-
bation, nonmigrating cells were scraped off from the upper surface of the filter. Migrating cells
were fixed with 4% paraformaldehyde and stained with 0.1% Crystal Violet in 20% methanol-
PBS for 3 min. To quantify migration, the bound stain was solubilized and absorbance mea-
sured at 590 nm. Each experiment was repeated at least three times in triplicate. Chemotactic
index was calculated from the number of cells migrating towards chemoattractant/number of
cells migrating towards vehicle control.
Phosphatase assay
Cells were resuspended with PBS, subjected to three rounds of freeze/thaw and then sonicated
for 10s. Serine/threonine and tyrosine phosphatase activities were measured using a commer-
cially available specific phosphatase assay kits (Molecular Probes Inc). Five micrograms of pro-
tein were used in the assay. The generated fluorescent product was determined using a
fluorometer (Ex 358 nm and Em 452 nm).
Data presentation
The results are presented as the mean ± SD or as representative results from more than three
different batches of cells, unless otherwise stated. Statistical significance was assessed by using
ANOVA followed by Bonferroni post-hoc testing, with Graph Pad Prism software, version 5
(GraphPad Software Inc).
Results
Leptin stimulates EGFR-independent proliferation of 1321N1 cells
We first checked for the constitutive expression of the leptin receptor (ObR) on human
1321N1 astrocytoma cells (Fig 1A). Then, we examined whether this expression could be
altered during exposure to proliferative agents also present in the tumor microenvironment.
As shown in Fig 1B, we found that cell stimulation increased constitutive ObR expression lev-
els on the cell surface. After a 24 h-stimulation with sPLA2-IIA, EGF or PGDR the population
of cells expressing high levels of OB-R increased from the 18% observed in control, to 42%,
45% and 66%, respectively.
We next analyzed leptin-induced proliferative responses in these cells, since cell growth is a
well-known effect of this adipokine in tumoral cells. As shown in Fig 1C, leptin enhanced
1321N1 cell proliferation in a dose-dependent manner and reached a 2.1 ± 0.4-fold (p0.001)
increase when stimulated with 0.5 μM leptin for 24h.
Moreover, we analyzed whether leptin-induced proliferative responses in 1321N1 cells
involved EGFR or PDGFR, important signaling mechanisms in cancer cells. We incubated
cells for 30 min in the presence of different doses of the EGFR kinase inhibitor AG1478 or the
PDGFR kinase inhibitor AG1296, before stimulation with 0.5 μM leptin or 0.4 μM EGF for
24h. The presence of specific inhibitors did not affect proliferation induced by leptin, whereas,
as expected, pretreatment with the EGFR kinase inhibitor AG1478 inhibited the EGF-induced
signalling and proliferation (Fig 1D).
Cross-Talk between leptin and sPLA2-IIA
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Fig 1. 1321N1 astrocytoma cells express the leptin receptor (ObR) and leptin stimulates EGFR-independent cell proliferation. (A) 1321N1 cells
immunofluorescence for ObR expression without and with primary anti-ObR antibody (H-300). Representative histograms. Unspecific staining, solid
grey curves. OB-R expression in cells treated as mentioned in the plot, open black curves (B) Cells stimulated for 18 h with the indicated agonist:
Expression of ObR was analyzed by flow cytometry. Serum-starved 1321N1 cells were stimulated for 24 h with increasing concentrations of leptin (C), or
with the indicated agonist in the presence or absence of specific inhibitors (D). Cell proliferation was measured as explained in Materials and Methods.
*p0.001 vs untreated control, +p0.001 vs EGF, n = 3
doi:10.1371/journal.pone.0170675.g001
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Leptin–induced Proliferation of 1321N1 cells requires the activity of
classical ERK, Akt, pathways
Next, to investigate whether the activation of Src/ERK/Akt/mTOR kinases were key elements
of the leptin induced proliferation in 1321N1 astrocytoma cells, they were incubated in the
absence or presence of an optimal concentration of human recombinant leptin (0.5 μM) at
different times. Flow cytometry analysis revealed that resting 1321N1 cells constitutively
expressed Tyr 416-phophorylated Src. Levels increased 4-fold over control by 3 min after lep-
tin treatment, and declined to near baseline levels by 30 min (Fig 2A).
We also found that leptin treatment immediately increased the presence of phosphorylated
extracellular signal regulated kinases (ERK, p-ERK), reaching a maximum level of phosphory-
lation around 10 min, decreasing afterwards to reach basal levels, approximately at 60 min (Fig
2A, S1A Fig).
Similarly, we observed Akt phosphorylation on Ser473 with a time course that paralleled
ERK activation/phosphorylation profile. In addition, the rapamycin-sensitive molecules P70
ribosomal protein S6 kinase (P70S6K) and S6 ribosomal protein (rS6) were also phosphory-
lated upon leptin exposure following a similar pattern, with a maximal effect at 15 min, which
almost disappeared 60 min after incubation. 1321N1 cells stimulated with 0.5 μg/ml of sPLA2-
IIA for 15 min were used as a positive control.
To identify the role of these signalling elements on leptin-induced astrocytoma cell growth,
the mitogenic response of 1321N1 cells to 0.5 μM of leptin was tested in the presence or
absence of several selective pharmacological inhibitors. As shown in Fig 2B, leptin-induced
proliferation was almost abolished by inhibition of ERK with the MEK inhibitor PD98059.
Inhibition of the PI3-kinase/Akt pathway with LY 294002, or with the specific mTOR inhibitor
rapamycin, also diminished cell proliferation in a concentration-dependent manner (Fig 2B).
We also found that 20 μM of the Src inhibitor, PP2, blocked leptin-induced cell proliferation
(not shown).
However, the presence of different doses of the PKC inhibitor GF109203X did not
markedly affect the response induced by leptin in 1321N1 cells (p>0.05) (Fig 2C and 2D, S1B
Fig), while EGF induced cell proliferation, as well as ERK and Akt phosphorylation, was abro-
gated by pre-treatment of the cells with 5 μM of GF109203X (p0.001).
To understand and further characterize the activation sequence of leptin in 1321N1 cells,
we incubated them in the presence or absence of selective inhibitors. We observed that ERK
phosphorylation was abolished by pretreatment of the cells with the MEK inhibitor PD98059,
which also abrogated activation of p70S6K and rS6, leaving Akt phosphorylation unaffected
(Fig 3A, S2A Fig). We also found that PP2, the Src inhibitor, blocked ERK phosphorylation
(data not shown). LY294002, the PI3K inhibitor, significantly reduced the phosphorylation of
Akt/p70S6K/rS6 signaling proteins, but it did not affect ERK (Fig 3B, S2B Fig) or Src (data not
shown) phosphorylation induced by leptin. In addition, rapamycin, the mTOR inhibitor, also
reduced p70S6K and rS6 phosphorylation (Fig 3C, S2C Fig).
Finally and as expected, the presence of the EGFR inhibitor, AG1478, did not affect leptin-
stimulated phosphorylation/activation of these signaling molecules, while it abolished EGF-
stimulated phosphorylation (Fig 3D, S2D Fig). The PDGFR kinase inhibitor AG1296 did not
abolish the immediate phosphorylation of the studied kinases either (not shown).
Leptin synergizes with sPLA2-IIA to induce proliferation of 1321N1 cells
Next, we compared the proliferative activity of leptin in 1321N1 cells with known mitogens
implicated in tumor pathogenesis such as EGF or sPLA2-IIA (Fig 4). As demonstrated previ-
ously, 0.5 μg/ml of sPLA2-IIA induced a strong mitogenic response in a serum-free cell culture
Cross-Talk between leptin and sPLA2-IIA
PLOS ONE | DOI:10.1371/journal.pone.0170675 March 1, 2017 6 / 22
020
40
60
80
100
0,0
0,5
1,0
1,5
2,0
Cross-Talk between leptin and sPLA2-IIA
PLOS ONE | DOI:10.1371/journal.pone.0170675 March 1, 2017 7 / 22
[23,24]. The simultaneous presence of 0.5 μM leptin and sPLA2-IIA, either at optimal (0.5 μg/
ml) or suboptimal (0.2 μg/ml) concentrations did not yield any significant additive effect (Fig
4A). Interestingly, although the addition of a suboptimal dose of leptin, 0.1 μM, to the optimal
concentration of sPLA2-IIA (0.5 μg/ml) had no major effect on the proliferative response of
the sPLA2-IIA, when it was combined with the lowest dose of the phospholipase, 0.2 μg/ml,
the proliferative response induced was significantly higher than promoted by either agonist
Fig 2. Intracellular pathways involved in the growth promoting effect of leptin in 1321N1 cells. (A) Cells were stimulated with 0.5 μM of leptin
for indicated times intervals, Src phosphorylation was analyzed by flow cytometry analysis, and ERK, Akt, P70S6K and rS6 phosphorylation were
determined by immunoblotting, using phospho-specific antibodies. (B) Cells were treated with the inhibitors, PD98059, LY294002 or rapamycin
before treatment with leptin, or with (C) GF109203X before treatment with leptin or EGF. After 24 h, cell proliferation was measured as explained in
Materials and Methods. (D) Cells treated as in (C) for 15 min. Protein phosphorylation was determined by immunoblotting, using phospho-specific
antibodies. *p0.001 vs untreated control, +p0.001 vs EGF, †p0.001 vs leptin treated, n = 3
doi:10.1371/journal.pone.0170675.g002
Fig 3. Effect of kinase inhibitors on the intracellular signaling mediators activated in leptin-treated cells. 1321N1 cells were incubated without or with
0.5 μM of leptin or 0.4 μM of EGF for 15 min in the presence or absence of the indicated inhibitors. Lysates were analysed by western blotting with the
specified antibodies.
doi:10.1371/journal.pone.0170675.g003
Cross-Talk between leptin and sPLA2-IIA
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Fig 4. Effect of leptin in sPLA2-IIA- and EGF-induced cell proliferation. Serum-starved 1321N1 cells
were stimulated for 24 h with the indicated concentrations of leptin, sPLA2-IIA (sPLA2) and EGF. Cell
proliferation was measured as explained in Materials and Methods. *p0.001 vs untreated control, #p0.001
vs sPLA2 alone, †p0.001 vs leptin alone, n = 3
doi:10.1371/journal.pone.0170675.g004
Cross-Talk between leptin and sPLA2-IIA
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alone (Fig 4B), suggesting the possibility that leptin synergizes with sPLA2-IIA to stimulate
growth.
Although EGF also induced a dose-dependent mitogenic response in the serum-free cul-
ture, the addition of 0.1 μM of leptin had no further effect on the proliferative activity of EGF
at any dose tested (Fig 4C), showing a specific link between sPLA2 and leptin signaling.
Leptin modulates migration of untreated and sPLA2-II-treated 1321N1
cells
We focussed on leptin and sPLA2-IIA, alone or combined, in the search for factors and mecha-
nisms involved in the invasive behaviour of brain tumors.
Experiments using leptin as a chemoattractant revealed a dose-dependent chemotactic
motility on these cells (Fig 5A). Besides, we also found that leptin increases their spontaneous
and FCS-mediated migratory capabilities in a concentration dependent manner. Pretreatment
of 1321N1 cells with the selective pharmacological inhibitors LY294002, PD98059 or rapamy-
cin reduced the chemoattractant capacity of leptin, as well as leptin-induced migration, both
baseline and FCS-mediated (Fig 5B).
Before searching for a cooperative effect between leptin and sPLA2-IIA, we assessed the
capacity of sPLA2-IIA to modulate 1321N1 migration. As shown in Table 1, sPLA2-IIA pre-
treatment stimulated both spontaneous and FCS-induced cell migration. Then, cells were
stimulated with a combination of sPLA2-IIA and leptin, at concentrations eliciting none or
minimal migratory responses, and we observed an increased cell mobilization compared to
either stimulus alone (Fig 5C). Likewise, addition of leptin to the lower transwell chamber,
at doses eliciting minor or no detectable chemoattractant effect in untreated cells, further
increased the migration of sPLA2-IIA-treated 1321N1 cells (Fig 5D).
Leptin modifies the temporal pattern of key signal-transduction elements
activated by sPLA2-IIA on 1321N1 cells
To elucidate the intracellular signaling mechanisms involved in the ability of leptin to potenti-
ate sPLA2-IIA-induced biological responses, we investigated whether 0.1 μM leptin altered the
time course of Src, ERK, Akt or p70S6 kinase activation induced by 0.2 μg/ml sPLA2-IIA. As
shown in Fig 6 and S3 Fig, there was little or no increase in the magnitude of phosphorylation
of the kinases studied after addition of a suboptimal dose of leptin (0.1 μM) to 1321N1 astrocy-
toma cells; however 0.2 μg/ml sPLA2-IIA led to a rapid transient activation of all the above
mentioned kinases. Interestingly, incubation of the cells with leptin and sPLA2-IIA simulta-
neously led to an immediate and sustained increase in the phosphorylation of ERK, Akt and
p70S6 kinase, up to 2h post stimulation. The effect on Src phosphorylation under these condi-
tions was less pronounced.
These results may suggest that the ability of leptin to potentiate sPLA2-IIA-induced prolif-
eration is due to the prolongation of sPLA2-IIA-induced kinases phosphorylation/activation.
Having previously established that sPLA2-IIA acts as a potent modulator of cell prolifera-
tion by inducing EGFR transactivation, we proposed to identify the potential role of EGFR in
mediating the cooperative actions of leptin and sPLA2-IIA.
A significant and sustained increase in EGFR phosphorylation (Tyr 1176, Tyr 1068 and Tyr
845) was observed upon sPLA2-IIA stimulation, either alone or in combination with leptin,
while leptin alone, as expected, showed no effect (Fig 7A). However, whereas in sPLA2-IIA-
stimulated cells EGFR phosphorylation level declined after 60 min of treatment, in cells treated
with sPLA2-IIA+leptin the tyrosine phosphorylation status of EGFR was maintained, at least,
2h after stimulation.
Cross-Talk between leptin and sPLA2-IIA
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Fig 5. Effects of leptin on the migration of untreated and sPLA2-IIA-treated cells. Cell mobility was
assayed using the 96-well Boyden chamber system. Serum-starved 1321N1 cells were untreated or treated
with the indicated concentration of leptin for 30 min, in the absence (A) or presence of kinase inhibitors (B).
Cells were allowed to migrate for 2 h to DMEM, FCS or leptin. *p<0.001 vs untreated cell towards DMEM,
**p<0.001 vs untreated cells towards FCS, †p<0.001 vs leptin-treated cell towards DMEM, ††p<0.001 vs
leptin-treated cell towards FCS, †††p0.001 vs untreated cell towards leptin, n = 3. Serum-starved 1321N1
Cross-Talk between leptin and sPLA2-IIA
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In keeping with these results, we showed that sPLA2-IIA- and sPLA2-IIA+leptin-mediated
responses were sensitive to EGFR inhibition (Fig 7B and 7C, S4 Fig). We found that AG1478
was able to inhibit not only sPLA2-IIA-stimulated growth, but also the synergistic effect of lep-
tin and sPLA2-IIA on 1321N1 cell proliferation. In addition, the persistent activation of the
selected signaling proteins induced by the simultaneous addition of sPLA2-IIA and leptin was
also dramatically reduced, particularly at later time points, where their phosphorylation was
close to basal levels.
Effect of leptin on protein phosphatase activity
Since the homeostasis of protein phosphorylation events is governed by kinases and phospha-
tases, we looked for changes in the phosphatase activity, as a putative mechanism involved in
the changes of the temporal phosphorylation pattern orchestrated by the presence of leptin. As
shown in Fig 8, we found that leptin stimulation, both alone and in the simultaneous presence
of sPLA2-IIA, decreased serine/threonine and tyrosine phosphatase activity in 1321N1 cells. In
contrast, incubation of intact cells with sPLA2-IIA alone did not affect the phosphatase activity
compared to non-stimulated cells. These findings suggest that sustained phosphorylation levels
in MAPKs, Akt and EGFR promoted by co-stimulation of leptin and sPLA2-IIA in 1321N1
astrocytoma cells might be partly attributed to a reduced phosphatase activity.
Synergistic stimulatory effects of the combination of leptin and sPLA2-IIA
on primary astrocyte cultures
Next, we extended these observations related to the synergistic interactions between leptin and
sPLA2-IIA to primary cultures of astrocytes. As shown in Fig 9A, cell proliferation was induced
in serum-starved astrocytes upon treatment with leptin and sPLA2-IIA. Alike in 1321N1 astro-
cytoma cells, a synergistic effect on cell growth was found when astrocytes were stimulated
with a suboptimal dose of leptin in combination with a suboptimal dose of sPLA2-IIA (Fig
9C). Then, we analyzed the activation/phosphorylation of some representative intracellular
signaling mediators associated with proliferation. Leptin and sPLA2-IIA increased ERK phos-
phorylation in a dose-dependent manner in primary cultures of astrocytes (Fig 9B). The simul-
taneous presence of both agonists at suboptimal doses also led to an immediate and sustained
increase in the phosphorylation of the studied signaling proteins (Fig 9D, S5 Fig), as previously
cells were treated as indicated for 30 min (loaded into top wells), and then allowed to migrate for 2 h to DMEM
(C), or treated with medium or sPLA2-IIA (sPLA2) for 30 min (loaded into top wells), and then allowed to
migrate for 2 h to DMEM or leptin (loaded into the bottom wells) (D). ‡ p0.001, n = 3.
doi:10.1371/journal.pone.0170675.g005
Table 1. sPLA2 treatment promotes 1321N1 cell migration.
Cell treatment Migration Index
DMEM DMEM + 50% FCS
None 1 ± 0.01 8.48 ± 0.02*
0.2μg/ml sPLA2 4.46 ± 0.01* 8.48 ± 0.02*
1μg/ml sPLA2 8.86 ± 0.03* 12.86 ± 0.02*,**
Cells were treated with different doses of sPLA2-IIA (sPLA2) for 30 min at 37˚C, and then allowed to migrate
towards DMEM or DMEM+FCS for 2h at 37˚C (see “Experimental Procedures” for calculation of relative
migratory index). The data represent the mean ± S.D for four independent experiments.
* and ** indicates p<0.001 relative to untreated cells migrating towards DMEM or DMEM+FCS,
respectively.
doi:10.1371/journal.pone.0170675.t001
Cross-Talk between leptin and sPLA2-IIA
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Fig 6. Effect of leptin+sPLA2-IIA treatment on the activation of intracellular kinases in 1321N1 cells. 1321N1 cells were stimulated with 0.1 μM of
leptin, 0.2 μg/ml of sPLA2-IIA (sPLA2) or both, for the indicated time intervals. Src phosphorylation was analyzed by flow cytometry analysis (A), and ERK,
Akt, P70S6K and rS6 phosphorylation were determined by immunoblotting, using phospho-specific antibodies (B).
doi:10.1371/journal.pone.0170675.g006
Cross-Talk between leptin and sPLA2-IIA
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Fig 7. Effect of leptin+sPLA2-IIA treatment on EGFR transactivation in 1321N1 cells. 1321N1 cells were stimulated with 0.1 μM of
leptin, 0.2 μg/ml of sPLA2-IIA (sPLA2) or both, in the presence or absence of 2.5 μM of AG1478. (A) At the indicated times, EGFR
phosphorylation was analyzed by flow cytometry analysis. (B) After 24 h cell proliferation was measured as explained in Materials and
Cross-Talk between leptin and sPLA2-IIA
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reported in 1321N1 astrocytoma cells. As expected, the presence of leptin, both alone or in the
presence of sPLA2-IIA, dramatically diminished the activity of both types of phosphatases
upon 30 min treatment (Fig 9E).
Methods. *p0.001 vs control without inhibitor, #p0.001 vs sPLA2 treated without inhibitor and ‡p0.001 vs leptin+sPLA2 treated
without inhibitor. (C) Phosphorylation of signaling proteins was determined by immunoblotting at the indicated times.
doi:10.1371/journal.pone.0170675.g007
Fig 8. Effect of leptin and sPLA2-IIA on phosphatases activity in 1321N1 cells. 1321N1 cells were stimulated with 0.1 μM of
leptin, 0.2 μg/ml of sPLA2-IIA (sPLA2) or both, for the indicated times. Ser/Thr phosphatase (A) and Tyr phosphatase (B) activity
was measured in the cell lysate. *p0.001 vs untreated control, #p0.001 vs sPLA2 alone, n = 3.
doi:10.1371/journal.pone.0170675.g008
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Discussion
This study provides possible mechanisms to better understand how obesity-related inflamma-
tion may affect risk and prognosis of multiple diseases. We focused on cancer and glial tumors
in particular, since a recent study shows that obesity worsens the prognosis of glioma patients
[4]. To date, the pathophysiology and molecular mechanisms underlying these associations are
not fully understood, although several hormonal systems—have been studied to some extent,
and a leptin-cytokine cross talk has been observed in breast cancer [26] The role of leptin and
sPLA2-IIA in the initiation and metastasis of tumors has been documented and reviewed, and
here we pay attention to both proteins as emerging candidate molecules linking obesity and
inflammation in glioma tumors [6,8,21].
This study illustrates key signaling molecules involved in leptin-induced proliferation and
migration of human astrocytoma cells, and demonstrates a cross-talk between leptin and the
inflammatory sPLA2-IIA. We observed that leptin increases the proliferative and migratory
effects of sPLA2-IIA on both astrocytoma cells and primary astrocytes. The synergy between
them is found at doses that individually show no activation, or activation below the reported
maximal effects. Synergy between inflammation-related factors has already been pointed as an
additional mechanism of the inflammatory system to sustain or amplify inflammatory
responses when suboptimal cytokine/chemokine concentrations are present [27–29].
Effects of leptin on different glioblastoma cell lines had been previously examined in vitro,
and leptin has been found: i) to induce migration and invasion of C6 rat cells linked to the acti-
vation of p38MAP kinase and NF-κB pathway, ii) to promote human U87 cells proliferation
mainly through Janus-Activated Kinase (JAK)/Signal Transducer and Activator of Transcrip-
tion 3 (STAT3) signaling pathway and iii) to enhance growth and migration of human LN18
and LN229 cells along with the activation of the PI-3K/Akt and STAT3 pathways [30–32]. The
present study reveals that leptin-induced human 1321N1 astrocytoma cells growth and mobil-
ity requires the activation of key intracellular signal transduction elements from the major sig-
nalling cascades: MEK/ERK and PI3K/Akt/mTOR/P70S6K pathways, but not PKC activation
as required by other proliferative molecules, such as EGF or sPLA2-IIA itself [24] Our data
also suggest that both cascades converge to regulate pro-tumoral events, since inhibition of
any of those pathways significantly diminishes leptin effects. Interestingly, although in some
cell types leptin signaling is dependent on EGFR transactivation, in 1321N1 astrocytoma cells
the presence of the specific EGFR inhibitor, AG1478, does not abrogate the mitogenic effects
induced by leptin alone [33].
The directed chemotactic migration of tumoral cells is an essential component of tumor
dissemination during progression and invasion. Here, we show that leptin not only behaves as
a chemoattractant for 1321N1 cells, but it also improves FCS-induced chemotaxis. These
results are inline with previous studies demonstrating cooperative chemotactic responses
between leptin and some mediators from the molecular network by which obesity impacts/
modifies? the pathological manifestation of carcinogenesis, such as IGF-I [19]. In addition, we
found that leptin-promoted chemotaxis of 1321N1 cells is dependent on activation/phosphor-
ylation of similar crucial kinases, hence signaling cascades, to leptin-induced mitogenesis.
Our study also found out that surface leptin receptor is enhanced by pro-inflammatory
sPLA2-IIA and growth factors, such as EGF and PDGF. Since inflammation and over-
Fig 9. Actions of leptin and sPLA2-IIA on mouse primary astrocytes. Astrocytes were stimulated with leptin, sPLA2-IIA (sPLA2) or
both, as indicated. (A, C) After 24 h cell proliferation was measured as explained in Materials and Methods. *p0.001 vs untreated
control cells, #p0.001 vs 0.2 μg/ml of sPLA2 alone, †p0.001 vs 0.1 μM of leptin alone, n = 3. (B, D) After 15 min, phosphorylation of
signaling proteins was determined by immunoblotting on the cell extracts. (E) At the indicated times, the activity of Ser/Thr- and Tyr-
phosphatase was measured in the cell lysate. *p0.001 vs untreated control, #p0.001 vs sPLA2 alone, n = 3.
doi:10.1371/journal.pone.0170675.g009
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expression of growth factors in glioma tumors involves pro-inflammatory proteins produc-
tion, including sPLA2-IIA; and these factors induce upregulation of the leptin receptor, it is
conceivable that leptin has a cooperative role. Leptin enhances sPLA2-IIA-mediated effects in
1321N1 astrocytoma cells, and sPLA2-IIA enhances leptin capacity to signal by inducing over-
expression of its receptor, thereby possibly contributing to a more aggressive behaviour of the
basal tumor phenotype.
sPLA2-IIA has been studied in different types of human malignancies, and it has been
shown to exert diverse, and even contradictory, biological effects, probably due to tissue- or
cell-specific functions [20,23,34]. We have previously reported that sPLA2-IIA mediates
1321N1 cell proliferation, and here we demonstrate that it also modulates astrocytoma cell
mobility. Additionally, we found that the rapid and transient activation of crucial kinases—
such as Src, ERK, Akt, P70S6K - induced by sPLA2-IIA are prolonged in time in the simulta-
neous presence of leptin. These amplifying effects of leptin in the phosphorylation state of
those signaling elements might be the cause of its synergistic effect, since a long-lasting phos-
phorylation could enhance the activity of the intracellular pathways involved in the prolifer-
ative and migratory responses to the phospholipase in 1321N1 cells.
Synergistic interactions between leptin and several factors have been previously described
in the regulation of diverse cell functions. Leptin interacts with cholecystokinin at the level of
vagal afferent neurons to control the function of the early growth response protein-1 (EGR1),
and synergistically increase phosphorylation of STAT3 to enhance neural excitability on the
nodose ganglia neurons [35,36]. Leptin also synergizes with stem cell factor in the stimulation
of murine hematopoietic progenitor cells proliferation, and with thyroid hormone to promote
growth plate chondrocyte proliferation and terminal differentiation [37,38]. A similar syner-
gism on the activation of intracellular kinases has been reported between leptin/IL-1 and lep-
tin/IFNγ to activate NOS type II in chondrocytes, and a synergistic activation of ERK and
EGFR has been associated with cell growth in oesophageal adenocarcinoma cells exposed to
leptin together with acid [39–41].
In 1321N1 cells, we identified EGFR phosphorylation upon sPLA2-IIA stimulation, and we
observed that the simultaneous presence of leptin prolonged its phosphorylation time-course,
although a direct action of leptin on EGFR phosphorylation was excluded analyzing results
from cells treated with leptin alone. Activation of the EGFR, by extracellular stimuli in addi-
tion to EGF-like ligands, is widely recognized as a potent signal in the regulation of diverse
biological processes including cell proliferation, survival and motility, depending on the cellu-
lar system, the stimulus and the repertoire of signaling molecules recruited [42]. Therefore, it
could be hypothesized that the sustained phosphorylation promoted by leptin on sPLA2-
IIA-EGFR transactivation is an important step in the cooperative effects of both proteins.
This prolonged phosphorylated status promoted by leptin when sPLA2-IIA is present,
would also be consistent with leptin acting through the regulation of the activity of serine/thre-
onine phosphatases and/or tyrosine phosphatases. It has been demonstrated that leptin
reduces the enzymatic activity of the serine/threonine phosphatase PP-1 in INS-1 cells, and
inhibits the phosphatase activity of the tyrosine phosphatase PTEN in mouse hypothalamic
cells and pancreatic β-cells [43,44]. Furthermore, it has been reported that inhibition of the
dual phosphatase MKP-1 increases ERK phosphorylation, and a prolonged EGFR phosphory-
lation is triggered upon inhibition of the dual protein phosphatase cdc25A, and the tyrosine
phosphatases PTP1B and SHP-2 [45–48]. In this study we find that in the presence leptin,
the activity of protein phosphatases is notably diminished. However, further studies should
be performed to elucidate whether leptin is either indirectly regulating protein phosphatase
inhibitors, or directly affecting the activity of protein phosphatases, and, if so, to identify the
phosphatase(s) responsible involved.
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This synergic interaction between leptin and sPLA2-IIA was also observed in primary astro-
cytes. Since sPLA2-IIA has been found upregulated in diseases that affect the nervous system,
such as stroke and Alzheimer’s disease, and these disorders are considered obesity-related dis-
eases, our results might also have relevance and contribute to explain some of the obesity-
related medical complications also in non-tumoral pathologies of the nervous system [49–51].
In conclusion, the synergic interaction between obesity- and inflammatory-related media-
tors provides an additional mechanism to sustain a harmful response in the presence of subop-
timal concentrations of either molecule. As a consequence, low concentrations of
inflammatory mediators in the tumor microenvironment, or in damaged brain areas, could be
stimulating cell growth and dissemination in overweight or obese subjects, thus being a mech-
anism by which obesity accelerates development and malignancy of cancer and other CNS
pathologies.
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Panel D. Bars are the the mean ± SD in arbitraty units, n = 3. #p0.001 vs sPLA2 alone.
(EPS)
Acknowledgments
We thank M.I. Cabero for her helpful technical assistance.
Author Contributions
Conceptualization: RM MLN.
Data curation: RM CC BG MH MLN.
Formal analysis: RM CC BG MH MLN.
Funding acquisition: MLN.
Investigation: RM CC BG.
Cross-Talk between leptin and sPLA2-IIA
PLOS ONE | DOI:10.1371/journal.pone.0170675 March 1, 2017 19 / 22
Methodology: RM CC BG MLN.
Project administration: MH MLN.
Resources: MLN.
Software: RM CC BG MH MLN.
Supervision: RM MH MLN.
Validation: RM CC BG MH MLN.
Visualization: RM CC BG MH MLN.
Writing – original draft: MH MLN.
Writing – review & editing: MH MLN.
References
1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer
in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348:1625–38. doi: 10.1056/
NEJMoa021423 PMID: 12711737
2. Haydon AM, Macinnis RJ, English DR, Giles GG. Effect of physical activity and body size on survival
after diagnosis with colorectal cancer. Gut 2006; 55:62–67 doi: 10.1136/gut.2005.068189 PMID:
15972299
3. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in
cancer patients with pre-existing diabetes mellitus. JAMA 2008; 300:2754–2764 doi: 10.1001/jama.
2008.824 PMID: 19088353
4. Chambless LB, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC. Type 2 diabetes mellitus and
obesity are independent risk factors for poor outcome in patients with high-grade glioma. J Neurooncol.
2012; 106:383–389. doi: 10.1007/s11060-011-0676-4 PMID: 21833800
5. van Greevenbroek MM, Schalkwijk CG, Stehouwer CD. Obesity-associated low-grade inflammation in
type 2 diabetes mellitus: causes and consequences. Neth J Med. 2013; 71:174–87. PMID: 23723111
6. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol. 2006; 207:12–22. doi: 10.1002/jcp.20472
PMID: 16110483
7. Konukoglu D, Uzun H, Firtina S, Cigdem Arica P, Kocael A, Taskin M. Plasma adhesion and inflamma-
tion markers: asymmetrical dimethyl-L-arginine and secretory phospholipase A2 concentrations before
and after laparoscopic gastric banding in morbidly obese patients. Obes Surg. 2007; 17:672–678.
PMID: 17658029
8. Lambeau G, Gelb MH. Biochemistry and physiology of mammalian secreted phospholipases A2. Annu
Rev Biochem. 2008; 77:495–520. doi: 10.1146/annurev.biochem.76.062405.154007 PMID: 18405237
9. Quach ND, Arnold RD, Cummings BS. Secretory phospholipase A2 enzymes as pharmacological tar-
gets for treatment of disease. Biochem Pharmacol. 2014; 90:338–348. doi: 10.1016/j.bcp.2014.05.022
PMID: 24907600
10. Riolfi M, Ferla R, Del Valle L, Piña-Oviedo S, Scolaro L, Micciolo R, et al. Leptin and its receptor are
overexpressed in brain tumors and correlate with the degree of malignancy. Brain Pathol. 2010;
20:481–489. doi: 10.1111/j.1750-3639.2009.00323.x PMID: 19775291
11. Howe LR, Subbaramaiah K, Hudis CA, Dannenberg AJ. Molecular pathways: adipose inflammation as
a mediator of obesity-associated cancer. Clin Cancer Res. 2013; 19:6074–6083 doi: 10.1158/1078-
0432.CCR-12-2603 PMID: 23958744
12. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395:763–
770. doi: 10.1038/27376 PMID: 9796811
13. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM. Leptin enters the brain by a saturable system
independent of insulin. Peptides 1996; 17:305–311 PMID: 8801538
14. Esler M, Vaz M, Collier G, Nestel P, Jennings G, Kaye D, et al. Leptin in human plasma is derived in
part from the brain, and cleared by the kidneys. Lancet 1998; 351:879–880.
15. Eikelis N, Lambert G, Wiesner G, Kaye D, Schlaich M, Morris M, et al. Extra-adipocyte leptin release in
human obesity and its relation to sympathoadrenal function. Am J Physiol Endocrinol Metab. 2004;286:
E774-E752.
Cross-Talk between leptin and sPLA2-IIA
PLOS ONE | DOI:10.1371/journal.pone.0170675 March 1, 2017 20 / 22
16. Fru¨hbeck G. Intracellular signalling pathways activated by leptin. Biochem J. 2006; 393:7–20. doi: 10.
1042/BJ20051578 PMID: 16336196
17. Fiorio E, Mercanti A, Terrasi M, Micciolo R, Remo A, Auriemma A, et al. Leptin/HER2 crosstalk in breast
cancer: in vitro study and preliminary in vivo analysis. BMC Cancer 2008; 8:305. doi: 10.1186/1471-
2407-8-305 PMID: 18945363
18. Soma D, Kitayama J, Yamashita H, Miyato H, Ishikawa M, Nagawa H. Leptin augments proliferation of
breast cancer cells via transactivation of HER2. J Surg Res. 2008; 149:9–14 doi: 10.1016/j.jss.2007.10.
012 PMID: 18262553
19. Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O’Regan RM, et al. Bidirectional cross-
talk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast
cancer cells via transactivation of epidermal growth factor receptor. Cancer Res. 2008; 68:9712–9722
doi: 10.1158/0008-5472.CAN-08-1952 PMID: 19047149
20. Dong Z, Liu Y, Scott KF, Gaitonde K, Bracken RB, Burke B, et al. Secretory phospholipase A2-IIa is
involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
Carcinogenesis. 2010; 31:1948–55 doi: 10.1093/carcin/bgq188 PMID: 20837598
21. Menschikowski M, Hagelgans A, Schuler U, Froeschke S, Rosner A, Siegert G. Plasma levels of phos-
pholipase A2-IIA in patients with different types of malignancies: prognosis and association with inflam-
matory and coagulation biomarkers. Pathol Oncol Res. 2013; 19:839–46. doi: 10.1007/s12253-013-
9652-y PMID: 23722320
22. Kupert E, Anderson M, Liu Y, Succop P, Levin L, Wang J, et al. Plasma secretory phospholipase A2-IIa
as a potential biomarker for lung cancer in patients with solitary pulmonary nodules. BMC Cancer.
2011; 11:513. doi: 10.1186/1471-2407-11-513 PMID: 22151235
23. Hernandez M, Burillo SL, Crespo MS, Nieto ML Secretory phospholipase A2 activates the cascade of
mitogenactivated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line
1321N1. J Biol Chem. 1998; 273:606–612. PMID: 9417122
24. Herna´ndez M, Martı´n R, Garcı´a-Cubillas MD, Maeso-Herna´ndez P, Nieto ML. Secreted PLA2 induces
proliferation in astrocytoma through the EGF receptor: another inflammation-cancer link. Neuro Oncol.
2010; 12:1014–1023. doi: 10.1093/neuonc/noq078 PMID: 20639215
25. Tusell JM, Ejarque-Ortiz A, Mancera P, SolàC, Saura J, Serratosa J. Upregulation of p21Cip1 in acti-
vated glial cells. Glia 2009; 57:524–534. doi: 10.1002/glia.20781 PMID: 18814231
26. Newman G, Gonzalez-Perez RR. Leptin-cytokine crosstalk in breast cancer. Mol Cell Endocrinol. 2014;
382:570–582. doi: 10.1016/j.mce.2013.03.025 PMID: 23562747
27. Sozzani S, Rieppi M, Locati M, Zhou D, Bussolino F, Proost P, et al. Synergism between platelet activat-
ing factor and CC chemokines for arachidonate release in human monocytes. Biochem Biophys Res
Commun. 1994; 199:761–766. PMID: 7510961
28. Gouwy M, Struyf S, Mahieu F, Put W, Proost P, Van Damme J. The unique property of the CC chemo-
kine regakine-1 to synergize with other plasma-derived inflammatory mediators in neutrophil chemo-
taxis does not reside in its NH2-terminal structure. Mol Pharmacol. 2002; 62:173–180. PMID: 12065768
29. Gouwy M, Struyf S, Catusse J, Proost P, Van Damme J. Synergy between proinflammatory ligands of
G proteincoupled receptors in neutrophil activation and migration. J Leukoc Biol. 2004; 76:185–194.
doi: 10.1189/jlb.1003479 PMID: 15075362
30. Yeh WL, Lu DY, Lee MJ, Fu WM. Leptin induces migration and invasion of glioma cells through MMP-
13 production. Glia 2009; 57:454–464. doi: 10.1002/glia.20773 PMID: 18814267
31. Han G, Wang L, Zhao R, Yue Z, Zhou X, Hu X, et al. Leptin promotes human glioblastoma growth
through activating Signal Transducers and Activators of Transcription 3 signaling. Brain Res Bull. 2012;
87:274–279 doi: 10.1016/j.brainresbull.2011.11.007 PMID: 22133921
32. Ferla R, Haspinger E, Surmacz E. Metformin inhibits leptin-induced growth and migration of glioblas-
toma cells. Oncol Lett. 2012; 4:1077–1081 doi: 10.3892/ol.2012.843 PMID: 23162655
33. Ogunwobi OO, Beales IL. Leptin stimulates the proliferation of human oesophageal adenocarcinoma
cells via HB-EGF and Tgfalpha mediated transactivation of the epidermal growth factor receptor. Br J
Biomed Sci. 2008; 65:121–127. PMID: 18986098
34. Wang X, Huang CJ, Yu GZ, Wang JJ, Wang R, Li YM, et al. Expression of group IIA phospholipase A2
is an independent predictor of favorable outcome for patients with gastric cancer. Hum Pathol. 2013;
44:2020–2027. doi: 10.1016/j.humpath.2013.01.027 PMID: 23664539
35. de Lartigue G, Lur G, Dimaline R, Varro A, Raybould H, Dockray GJ. EGR1 Is a target for cooperative
interactions between cholecystokinin and leptin, and inhibition by ghrelin, in vagal afferent neurons.
Endocrinology 2010; 151:3589–3599 doi: 10.1210/en.2010-0106 PMID: 20534729
36. Heldsinger A, Grabauskas G, Song I, Owyang C. Synergistic Interaction between Leptin and Cholecys-
tokinin in the Rat Nodose Ganglia Is Mediated by PI3K and STAT3 Signaling Pathways: Implications for
Cross-Talk between leptin and sPLA2-IIA
PLOS ONE | DOI:10.1371/journal.pone.0170675 March 1, 2017 21 / 22
leptin as a regulator of short term satiety. J Biol Chem. 2011; 286:11707–11715. doi: 10.1074/jbc.M110.
198945 PMID: 21270124
37. Umemoto Y, Tsuji K, Yang FC, Ebihara Y, Kaneko A, Furukawa S, et al. Leptin Stimulates the Prolifera-
tion of Murine Myelocytic and Primitive Hematopoietic Progenitor Cells. Blood 1997; 90:3438–3443.
PMID: 9345027
38. Wang L, Shao YY, Ballock RT. Leptin synergizes with thyroid hormone signaling in promoting growth
plate chondrocyte proliferation and terminal differentiation in vitro. Bone. 2011; 48:1022–1027. doi: 10.
1016/j.bone.2011.02.012 PMID: 21349356
39. Otero M, Lago R, Lago F, Reino JJ, Gualillo O. Signalling pathway involved in nitric oxide synthase type
II activation in chondrocytes: synergistic effect of leptin with interleukin-1. Arthritis Res Ther. 2005; 7:
R581–R591. doi: 10.1186/ar1708 PMID: 15899045
40. Otero M, Lago R, Go´mez R, Lago F, Gomez-Reino JJ, Gualillo O. Phosphatidylinositol 3-kinase, MEK-
1 and p38 mediate leptin/interferon-gamma synergistic NOS type II induction in chondrocytes. Life Sci.
2007; 81:1452–1460. doi: 10.1016/j.lfs.2007.09.007 PMID: 17935739
41. Beales IL, Ogunwobi OO. Leptin synergistically enhances the anti-apoptotic and growth-promoting
effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol. 2007;
274:60–68. doi: 10.1016/j.mce.2007.05.017 PMID: 17618045
42. Liebmann C. EGF receptor activation by GPCRs: an universal pathway reveals different versions. Mol
Cell Endocrinol. 2011; 331:222–31. doi: 10.1016/j.mce.2010.04.008 PMID: 20398727
43. Ning K, Miller LC, Laidlaw HA, Burgess LA, Perera NM, Downes CP, et al. A novel leptin signalling path-
way via PTEN inhibition in hypothalamic cell lines and pancreatic beta-cells. EMBO J. 2006; 25:2377–
2387 doi: 10.1038/sj.emboj.7601118 PMID: 16675953
44. Kuehnen P, Laubner K, Raile K, Scho¨fl C, Jakob F, Pilz I, et al. Protein phosphatase 1 (PP-1)-depen-
dent inhibition of insulin secretion by leptin in INS-1 pancreatic β-cells and human pancreatic islets.
Endocrinology. 2011; 152:1800–1808. doi: 10.1210/en.2010-1094 PMID: 21427225
45. Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP
kinase function. FASEB J 2000; 14:6–16. PMID: 10627275
46. Wang Z, Wang M, Lazo JS, Carr BI. Identification of epidermal growth factor receptor as a target of
Cdc25A protein phosphatase. J Biol Chem. 2002; 277:19470–19475. doi: 10.1074/jbc.M201097200
PMID: 11912208
47. Iwamoto N, Sumi D, Ishii T, Uchida K, Cho AK, Froines JR, et al Chemical knockdown of protein-tyro-
sine phosphatase 1B by 1,2-naphthoquinone through covalent modification causes persistent transacti-
vation of epidermal growth factor receptor. J Biol Chem. 2007; 282:33396–33404 doi: 10.1074/jbc.
M705224200 PMID: 17878162
48. Liu JC, Chen CH, Chen JJ, Cheng TH. Urotensin II induces rat cardiomyocyte hypertrophy via the tran-
sient oxidization of Src homology 2-containing tyrosine phosphatase and transactivation of epidermal
growth factor receptor. Mol Pharmacol. 2009; 76:1186–1195 doi: 10.1124/mol.109.058297 PMID:
19755521
49. Moses GS, Jensen MD, Lue LF, Walker DG, Sun AY, Simonyi A, et al. Secretory PLA2-IIA: a new
inflammatory factor for Alzheimer’s disease. J Neuroinflammation. 2006; 3:28. doi: 10.1186/1742-2094-
3-28 PMID: 17026770
50. Naderali EK, Ratcliffe SH, Dale MC. Obesity and Alzheimer’s disease: a link between body weight and
cognitive function in old age. Am J Alzheimers Dis Other Demen. 2009; 24:445–449. doi: 10.1177/
1533317509348208 PMID: 19801534
51. Yagami T, Yamamoto Y, Koma H. The Role of Secretory Phospholipase A2 in the Central Nervous Sys-
tem and Neurological Diseases. Mol Neurobiol. 2014; 49:863–876. doi: 10.1007/s12035-013-8565-9
PMID: 24113843
Cross-Talk between leptin and sPLA2-IIA
PLOS ONE | DOI:10.1371/journal.pone.0170675 March 1, 2017 22 / 22
